<DOC>
	<DOCNO>NCT02405988</DOCNO>
	<brief_summary>Overdose potential deadly outcome serious problem among opioid abuser , least Norway . To save life , immediate treatment Î¼-opioid antidote naloxone require . The purpose study explore pharmacokinetics pharmacodynamics naloxone healthy volunteer opioid influence .</brief_summary>
	<brief_title>Pharmacodynamics Arteriovenous Differences Naloxone Healthy Participants Exposed Opioid</brief_title>
	<detailed_description>Healthy volunteer bring state opioid influence well-known , short acting , control safe manner use remifentanil . This create strong opioid effect induce miosis , reduce respiration reduce sensation pain , three strong indicator opiate . Naloxone counteract effect , measure change pupillary size . Blood sample naloxone remifentanil also take . Naloxone well-known , well-tolerated drug excellent safety profile many decade use . The formulation use trial hold market authorization . Care take include opioid user study naloxone would precipitate acute withdrawal . Also possible drug misusers exclude well people access remifentanil infusion equipment daily work , although abuse potential highly specialise drug minimal . By weigh syrinx discharge reliability dose deliver confirm .</detailed_description>
	<mesh_term>Drug Overdose</mesh_term>
	<mesh_term>Analgesics , Opioid</mesh_term>
	<mesh_term>Remifentanil</mesh_term>
	<mesh_term>Naloxone</mesh_term>
	<criteria>American Society Anesthesiologists ( ASA ) class I ECG without pathologic abnormality BMI range 18,5 26 kg/m2 pas modify allens test determine collateral circulation hand lab value within reference value St Olav 's Hospital relevant haematological biochemical test inclusion : Haemoglobin ( male : 13.417.0 g/dL , female 11.7 15.3 g/dL ) Creatinine ( male : 60105 micromole/L , female 45 90 micromole/L ) Aspartate aminotransferase ( ASAT ) ( male : 1545 U/L , female : 1535 U/L ) Alanine transaminase ( ALAT ) ( male : 1070 U/L , female : 1045 U/L ) Gamma glutamyl transpeptidase ( GT ) ( male : 1080 U/L , female : 1045 U/L ) For woman reproductive age : serum HCG ( normal 3 ye/L ) Signed informed consent expect cooperation subject treatment Taking medication include herbal medicine last week prior treatment visit Current history drug and/or alcohol abuse ( To assess problematic drug alcohol use use CAGE AID screen tool ) History contact police authority relation alcohol drug offence History prolong use opioid analgesic History prior drug allergy Pregnant woman ( HCG 3 ye/L inclusion ) Women reproductive age use high efficacy contraceptive ( Oral contraceptive , Patch ( Evra ) , Implants , Vaginal ring , Hormonal IUD , Copper intrauterine device ( IUD ) , Sterilization ) throughout study period last visit . Breastfeeding woman Participants access remifentanil potent opioids daily workplace . Hypersensitivity naloxone , remifentanil hydrochloride lidocaine and/or excipients . Participants participate previous trial receive remifentanil opioids . Participants donate 450 ml blood within 6 week prior visit 2 , plan donate blood within 6 week visit 2 Any reason , opinion investigator , patient participate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Emergency Treatment</keyword>
	<keyword>Morphine Derivates</keyword>
	<keyword>Heroin</keyword>
	<keyword>Antidotes</keyword>
	<keyword>Administration , Intravenous</keyword>
	<keyword>Pharmacology</keyword>
	<keyword>Naloxone</keyword>
	<keyword>Healthy volunteer</keyword>
</DOC>